Irreversible enzyme inhibitors. 173. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000138:chemical synthesis / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D046508:Culture Techniques; D005493:Folic Acid Antagonists; D007414:Intestinal Neoplasms / Q000188:drug therapy; D007680:Kidney Neoplasms / Q000188:drug therapy; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D051381:Rats; D013160:Splenic Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014227:Triazines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D014227:Triazines